Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528987 | 0.85 | PTGDR2 (0.55) | PTPN7ALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL8402084 | 0.85 | ALDH1A1 (0.56) | PTPN7ALDH1A1TSHRHSD17B10MCL1 | |
| SCHEMBL3301562 | 0.85 | PPARD (0.66) | PTPN7ALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL29712519 | 0.84 | ALDH1A1 (0.58) | ALDH1A1TSHRMCL1PPARDPOLB | |
| SCHEMBL11887758 | 0.84 | ALDH1A1 (0.58) | ALDH1A1ALOX15TSHRHSD17B10L3MBTL1 | |
| SCHEMBL31186568 | 0.81 | PTPN11 (0.57) | ALDH1A1TSHRPOLB | |
| SCHEMBL930228 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRHSD17B10LMNAMAPT | |
| SCHEMBL15787044 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRPPARDL3MBTL1FFAR1 | |
| SCHEMBL4076964 | 0.79 | PTPN7 (0.85) | PTPN7ALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL14104475 | 0.79 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-0603731-B1 | Purification of liquid crystals and liquid crystal composition | HITACHI CHEMICAL CO LTD (JP) | 1998-03-11 | — | — | EP | disclosed |
| US-5540857-A | Purification of liquid crystals and liquid crystal composition | HITACHI CHEMICAL CO., LTD. (JP) | 1996-07-30 | — | — | US | disclosed |
| US-5422034-A | Treating with porous polyimide particles; high voltage retention and high display properties | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0603731-A1 | Purification of liquid crystals and liquid crystal composition | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-4791157-A | REACTING TRIMELLITIC ACID WITH AROMATIC DIAMINE WITH ETHER GROUPS | HITACHI CHEMICAL CO. (JP) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | PTPN7 4001/4885ALDH1A1 2182/4885ALOX15 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.